Building a Fat-Loss Peptide Stack — The Mechanism-Layering Approach

Most people running peptides for fat loss are pulling one lever. The better outcome comes from pulling several levers that hit different mechanisms at once — because fat loss isn't governed by a single system. Appetite, glucose handling, lipolysis, mitochondrial energy output, and growth-hormone pulsatility are separate biological systems, and a single-compound protocol only engages one of them while the rest sit at baseline. That's why single-peptide protocols so often hit diminishing returns.

The shift that changes outcomes: stop asking "which peptide is the strongest fat-burner?" and start asking "which combination of mechanisms keeps every fat-loss pathway working at once?"

The four-layer framework

These mechanisms complement each other rather than compete. The GLP-class layer drives the systemic fat-loss demand. The mitochondrial pair makes sure your cells can actually handle that demand. The GH-axis layer protects lean tissue against the muscle-loss tail that shows up across the entire GLP-1 class. None of these is the "right" single tool — they're four separate levers.

Layer 1 — the GLP-class anchor

This is the compound driving the systemic signaling: satiety, slowed gastric emptying, and — with the dual and triple agonists — additional insulin-sensitivity and liver-fat-mobilization effects.

• Semaglutide — single GLP-1 receptor agonist, the molecule that established the GLP-1 obesity paradigm. Deepest published RCT base in the category (STEP-1, STEP-2), FDA-approved for chronic weight management (Wegovy) and type 2 diabetes (Ozempic). A legitimate first-line option — prescriber familiarity, insurance coverage, accessible compounded versions.
• Tirzepatide — dual GLP-1 + GIP agonist. The GIP arm works synergistically with GLP-1 to improve insulin sensitivity and fat oxidation. Clinical data (SURMOUNT-1, SURMOUNT-2) consistently outperforms semaglutide on total weight loss, with a better-tolerated side-effect profile for most users.
• Retatrutide — triple agonist (GLP-1 + GIP + glucagon receptors), the strongest of the three. The glucagon arm signals the liver to mobilize stored fat and increases thermogenesis, pushing fat oxidation even at rest. In the Phase 2 trial, participants on the 12 mg/week dose lost an average of 24.2% of body weight at 48 weeks, versus 2.1% on placebo (Jastreboff et al., NEJM 2023, PMID 37366315).

The class-wide caveat: every GLP-class compound carries a muscle-loss tail when run without supportive structure — the body doesn't discriminate between fat and lean tissue under a steep deficit. That's solved by the foundation, not by picking a different molecule: roughly 1 g of protein per pound of target body weight, resistance training, creatine, and the GH-axis layer below. If you only have access to semaglutide, a well-supported semaglutide protocol beats a retatrutide protocol run without that foundation.

Layer 2 — mitochondrial biogenesis (MOTS-c)

Layer 1 places real metabolic demand on your cells. MOTS-c is a mitochondrial-derived peptide — encoded in your own mitochondrial DNA — that activates AMPK, one of the body's central metabolic switches, signaling cells to burn fat for fuel. It also improves insulin sensitivity, raises metabolic rate without stimulating the central nervous system, and acts as an exercise mimetic, with animal-model research showing anti-obesity effects independent of caloric intake. Practitioners commonly run it at 5–10 mg/week SubQ, sometimes split into 2–4 mg administrations across the week.

Layer 3 — mitochondrial protection (SS-31)

Where MOTS-c activates the machinery, SS-31 (Elamipretide) repairs it. As mitochondria age, the inner membrane where ATP is actually produced deteriorates, cells produce less energy, and fat-burning becomes less efficient. SS-31 targets that membrane directly, binds cardiolipin, and reduces oxidative stress. It isn't a dramatic standalone fat-burner — the point is that every other compound in the stack works better when mitochondria are healthy. It's also the first FDA-approved mitochondrial-targeted peptide (Barth syndrome, 2025 approval), giving it the strongest regulatory record of any compound in this category, plus a secondary cardiovascular benefit nothing else in the stack offers. Typical dosing is 5–10 mg/day SubQ.

Layer 4 — GH-axis optimization

Eight weeks into a real caloric deficit, muscle preservation becomes as important as continued fat loss.

Tesamorelin is a GHRH analog that stimulates the pituitary to release growth hormone in a physiological pulse pattern — your own GH, not synthetic HGH from outside. It's the only GH-axis peptide specifically developed and FDA-approved to target visceral fat (HIV-associated lipodystrophy; used off-label for visceral fat generally), and it has a notably clean side-effect profile relative to other GH-axis peptides. Typical dosing is 0.5–1 mg SubQ, five days a week, before bed.

CJC-1295/Ipamorelin pairs a GHRH analog (CJC-1295) with a ghrelin-receptor agonist (Ipamorelin) that also suppresses somatostatin, the hormone that shuts GH production down. Together they produce a larger, cleaner GH pulse than either alone — better fat oxidation, muscle retention, recovery, and sleep. It's the broader, more accessible GH-axis entry point versus Tesamorelin's more targeted visceral-fat effect. Typical dosing is 200–400 mcg CJC-1295 with 100–300 mcg Ipamorelin, taken together before bed, five days a week.

Sequencing it over 12 weeks

Adding all four layers on day one makes it impossible to tell what's doing what, and the side-effect burden is unmanageable. A more sensible sequence:

1. Week 1 — Start the GLP-class compound alone, at the lowest titration dose (for retatrutide, 0.5 mg SubQ weekly). No other peptides yet.
2. Weeks 2–7 — Titrate the GLP-class compound up slowly (retatrutide to roughly 3–4 mg/week over 6–8 weeks). This is also when the foundation gets locked in: protein target, resistance training 3–4x/week, creatine, sleep, hydration.
3. Weeks 2–8 — Once the GLP-class compound is tolerating well, add MOTS-c and SS-31 together. The metabolic demand from Layer 1 is real; the mitochondrial pair keeps cellular output at full capacity.
4. Week 8+ — Add the GH-axis layer once lean-tissue preservation becomes the priority — CJC-1295/Ipamorelin for broader systemic GH support, Tesamorelin for visceral-fat targeting specifically, or both for an advanced 90+ day protocol.
5. Week 12 — All four mechanisms running together: appetite regulation, mitochondrial efficiency, and GH-axis support, built up in sequence rather than piled on at once.

Other compounds people ask about

A few fat-loss peptides come up often but don't make this core stack:

• AOD-9604 — a synthetic fragment of the growth-hormone molecule. Stimulates lipolysis and inhibits fat storage, but completed Phase II obesity trials showed negative efficacy and the developer abandoned it. It may have a role as a minor supporting compound layered on Tesamorelin or CJC-1295/Ipamorelin — not as a primary tool.
• SLU-PP-332 — an exercise-mimetic compound working through the estrogen-related receptor pathway. Early animal signals are promising and the mechanism is sound, but robust human data doesn't exist yet, and its short half-life means frequent dosing. Worth watching, not yet worth anchoring a stack on.
• 5-Amino-1MQ — an orally bioavailable small molecule that inhibits NNMT and targets adipose tissue directly. Underwhelming as a standalone for fat loss; its more useful niche is supporting the metabolic environment during a transition off a primary GLP-class peptide.

Why Melanotan II isn't on this list

Melanotan II activates the MC4R appetite-suppressing pathway — the same target pharmaceutical companies are pursuing for next-generation obesity drugs — but it does so non-selectively across multiple melanocortin receptors. That brings a rough side-effect list: nausea, facial flushing, elevated blood pressure, darkening of moles with documented melanoma-adjacent concerns, and reports of rhabdomyolysis and acute kidney injury. The fat-loss effect doesn't justify that risk profile when the four-layer stack above exists as a cleaner alternative.

Sourcing it responsibly

Every compound in this stack is only as good as the vial it comes in. Work only with vendors who provide a real third-party Certificate of Analysis, and read up on how to actually read one before you buy — see the full list of vetted sources on this site.

Educational information only, not medical advice. Retatrutide, tirzepatide, semaglutide, MOTS-c, SS-31, tesamorelin, and CJC-1295/Ipamorelin are sold for research use only and are not FDA-approved for human use outside their specific approved indications.

Sources: Jastreboff et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity," NEJM 2023 (PMID 37366315). See also: Semaglutide, Tirzepatide, MOTS-c, and creatine as a GLP-1 adjunct.